Identification of Kazal Inhibitor Scaffolds with Identical Canonical Binding Loops and Their Effects on Binding Properties.
Journal
Biochemistry
ISSN: 1520-4995
Titre abrégé: Biochemistry
Pays: United States
ID NLM: 0370623
Informations de publication
Date de publication:
17 01 2023
17 01 2023
Historique:
pubmed:
5
1
2023
medline:
19
1
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
Kazal inhibitors hold high potential as scaffolds for therapeutic molecules, taking advantage of the easily exchangeable canonical binding loop. Different Kazal inhibitor backbones have been suggested to be therapeutically useful, but the impact of different Kazal-like scaffolds on binding properties is still largely unknown. Here, we identified trypsin-targeting human serine protease inhibitor Kazal type 1 (SPINK1) homologues in different mammalian species that cluster in two P2-P1 combinations, implying the coevolution of these residues. We generated loop exchange variants of human SPINK1 for comparison with Kazal inhibitors from related species. Using comprehensive biophysical characterization of the inhibitor-enzyme interactions, we found not only affinity but also pH resistance to be highly backbone-dependent. Differences are mostly observed in complex stability, which varies by over one order of magnitude. We provide clear evidence for high backbone dependency within the Kazal family. Hence, when designing Kazal inhibitor-based therapeutic molecules, testing different backbones after optimizing the canonical binding loop can be beneficial and may result in increased affinity, complex stability, specificity, and pH resistance.
Identifiants
pubmed: 36598875
doi: 10.1021/acs.biochem.2c00573
pmc: PMC9850914
doi:
Substances chimiques
SPINK1 protein, human
0
Trypsin
EC 3.4.21.4
Trypsin Inhibitor, Kazal Pancreatic
50936-63-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-542Références
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1410-5
pubmed: 11171964
ACS Chem Biol. 2022 Apr 15;17(4):969-986
pubmed: 35378038
Cell Mol Life Sci. 2003 Nov;60(11):2427-44
pubmed: 14625687
Sci Rep. 2019 Aug 7;9(1):11436
pubmed: 31391482
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
J Mol Biol. 2000 Feb 18;296(2):325-34
pubmed: 10669590
Molecules. 2021 Dec 14;26(24):
pubmed: 34946663
PLoS One. 2015 May 15;10(5):e0125376
pubmed: 25978745
J Mol Biol. 2019 Feb 1;431(3):557-575
pubmed: 30543823
Chembiochem. 2010 Nov 22;11(17):2341-6
pubmed: 21053238
Nucleic Acids Res. 2018 Jul 2;46(W1):W315-W322
pubmed: 29893907
Nucleic Acids Res. 2016 Jul 8;44(W1):W344-50
pubmed: 27166375
J Biol Chem. 2000 Oct 27;275(43):33346-52
pubmed: 10930417
J Mol Biol. 2018 Jul 20;430(15):2237-2243
pubmed: 29258817
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11034-9
pubmed: 19549826
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
J Biol Chem. 2010 Nov 19;285(47):36884-96
pubmed: 20861008
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
Proteins. 1998 Sep 1;32(4):459-74
pubmed: 9726416
J Biol Chem. 1973 Mar 10;248(5):1760-71
pubmed: 4735140
Biochemistry. 1997 Feb 18;36(7):1598-607
pubmed: 9048543
Annu Rev Biochem. 1980;49:593-626
pubmed: 6996568
Int J Mol Sci. 2022 Mar 23;23(7):
pubmed: 35408828
Expert Opin Pharmacother. 2009 Dec;10(18):2999-3014
pubmed: 19925044
Eur J Biochem. 1992 Mar 1;204(2):433-51
pubmed: 1541261
Biochem Biophys Res Commun. 1967 Apr 20;27(2):157-62
pubmed: 6035483
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638